CD44 and cancer: The specific binding of HA to CD44 and the possibility of exploiting the EPR effect could provide an option for nanocarrier active tumor targeting, allowing enhanced cancer cell uptake via the HA-CD44 receptor-mediated endocytosis pathway [11].